Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy
This open-label prospective phase I/IIa clinical study used autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) followed by mesenchymal stromal cells conditioned media (MSC-CM) for the first time to treat multiple sclerosis (MS) patients. [pdf-embedder url="https://www.nsorm.com/wp-content/uploads/2018/07/MSCs-in-Tx-of-MS-Sept.-2017.pdf" title="MSC's in Tx of MS Sept. 2017"]